NCT02070939View on ClinicalTrials.gov

Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Healthy
Interventions
DRUG

PF-06260414

Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format

DRUG

Placebo

Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format

DRUG

PF-06260414

Subjects will receive PF-06260414 doses (solution) twice daily for 14 days

DRUG

Placebo

Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days

DRUG

PF-06260414

Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days

DRUG

Placebo

Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02070939 - Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects | Biotech Hunter | Biotech Hunter